The historical rank and industry rank for Myovant Sciences's Net Cash per Share or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Cash Ratio of Myovant Sciences was 47.27. The lowest was 0.00. And the median was 25.82.
Myovant Sciences Net Cash per Share Historical Data
The historical data trend for Myovant Sciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Net Cash per Share
0.45
-0.17
-1.50
-4.33
-5.90
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Net Cash per Share
-4.33
-6.06
-4.80
-5.43
-5.90
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Net Cash per Share, along with its competitors' market caps and Net Cash per Share data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Net Cash per Share Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Net Cash per Share distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Net Cash per Share falls into.
Myovant Sciences Net Cash per Share Calculation
In the calculation of a company's net cash, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative net cash. But sometimes a company's price may be lower than its net-cash.
Myovant Sciences's Net Cash Per Share for the fiscal year that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener. GuruFocus also publishes a monthly Net-Net newsletter.
Myovant Sciences Net Cash per Share Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.41(4.07%) Volume: 479,709 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
